Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Approximately 8% to 19% of patients with acute myeloid leukemia (AML) have isocitrate dehydrogenase-2 (IDH2) mutations, which occur at active site arginine residues R140 and R172. IDH2 mutations produce an oncometabolite, 2-hydroxyglutarate (2-HG), which leads to DNA and histone hypermethylation and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Stein, Eytan M., DiNardo, Courtney D., Fathi, Amir T., Pollyea, Daniel A., Stone, Richard M., Altman, Jessica K., Roboz, Gail J., Patel, Manish R., Collins, Robert, Flinn, Ian W., Sekeres, Mikkael A., Stein, Anthony S., Kantarjian, Hagop M., Levine, Ross L., Vyas, Paresh, MacBeth, Kyle J., Tosolini, Alessandra, VanOostendorp, Jason, Xu, Qiang, Gupta, Ira, Lila, Thomas, Risueno, Alberto, Yen, Katharine E., Wu, Bin, Attar, Eyal C., Tallman, Martin S., de Botton, Stéphane
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2019
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6384189/
https://ncbi.nlm.nih.gov/pubmed/30510081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-08-869008
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge